Results 131 to 140 of about 1,190,584 (342)

Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies

Pharmacogenomics and Personalized Medicine, 2013
Marybeth Sechler,1,2 Amber D Cizmic,3 Sreedevi Avasarala,1 Michelle Van Scoyk,1 Christine Brzezinski,1 Nicole Kelley,1 Rama Kamesh Bikkavilli,1 Robert A Winn1–3 1Division of Pulmonary Sciences and Critical Care, 2Program in Cancer Biology ...
Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA   +7 more
doaj  

Evaluation of the 3‐minute chair rise test as part of preoperative evaluation for patients with non‐small cell lung cancer

, 2020
Mathilde Azzi, David Debeaumont, Tristan Bonnevie, B. Aguilaniu, Damiano Cerasuolo, Fairuz Boujibar, A. Cuvelier, Francis‐Edouard Gravier   +7 more
openalex   +1 more source

Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer

, 2022
Yue Zheng, Peipei Wang, Yang Fu, Yue-yun Chen, Zhenyu Ding   +4 more
openalex   +1 more source

LncRNA RP11-58O9.2 predicts poor prognosis and promotes progression of non-small cell lung cancer [PDF]

, 2023
Xuan Miao, Wen Xi, Yongxia Bao
openalex   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond

Therapeutics and Clinical Risk Management, 2011
Bruno Gori1, Serena Ricciardi1, Alberto Fulvi1, Salvatore Intagliata2, Ester Del Signore1, Filippo de Marinis11Oncological-Pulmonary Unit 1st, San Camillo Hospital, Rome, Italy; 2Department of Medical Oncology, University Campus Bio-Medico, Rome ...
Gori B, Ricciardi S, Fulvi A, Intagliata S, Del Signore E, de Marinis F   +5 more
doaj  

Mutations of the EPHB6 Receptor Tyrosine Kinase Induce a Pro-Metastatic Phenotype in Non-Small Cell Lung Cancer

, 2013
Alterations of Eph receptor tyrosine kinases are frequent events in human cancers. Genetic variations of EPHB6 have been described but the functional outcome of these alterations is unknown.
Bulk, E.M. (Etmar), Hascher, A. (Antje), Hillejan, L. (Ludger), Koschmieder, S. (Steffen), Krug, U. (Utz), Marra, A. (Alessandro), Müller-Tidow, C. (Carsten), Timmermann, B. (Bernd), Wiewrodt, R.G. (Rainer), Yu, J. (Jun)   +9 more
core   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Iterative surgical resections in non-small cell lung cancer

Polish Journal of Thoracic and Cardiovascular Surgery, 2022
Ahmet Ucvet, Serkan Yazgan, Ozgur Samancilar, Soner Gursoy, Ahmet Emin Erbaycu, Berna Komurcuoglu   +5 more
doaj   +1 more source